Etanercept-induced pleuropericardial lupus-like syndrome.

  title={Etanercept-induced pleuropericardial lupus-like syndrome.},
  author={Ilias Porfyridis and Ioannis Kalomenidis and Ioannis Psallidas and Grigoris K. Stratakos and Ch Roussos and Theodoros Vassilakopoulos and Georgios T Stathopoulos},
  journal={The European respiratory journal},
  volume={33 4},
Tumour necrosis factor (TNF)-a is currently being targeted in autoimmune joint diseases, including rheumatoid arthritis (RA) and spondylarthropathies [1, 2]. Widespread use of antiTNF-a therapies (e.g. etanercept) has unveiled a spectrum of adverse effects, including infection [3] and a systemic lupus erythematosus (SLE)-like syndrome [4]. The latter… CONTINUE READING